JPRN-jRCTs051200036已完成2 期
Efficacy and safety of nintedanib on lung fibrosis in severe pneumonia induced by coronavirus disease 2019: Historical control study.
memura Yutaka0 个研究点目标入组 30 人开始时间: 2020年7月27日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 30
研究概览
简要总结
Thirty patients were in nintedanib group and 30 patients were in control group. There were no significant differences in 28-day mortality between the groups. Lengths of mechanical ventilation were significantly shorter in the nintedanib group. Computed tomography volumetry showed that the percentages of high-attenuation areas were significantly lower in the nintedanib group.These finding suggested that the administration of nintedanib may offer potential benefits for minimizing lung injury in COVID-19.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1) Obtaining sufficient informed consent for this trials from participates or their close relatives
- •2) 20 years or older at the time of informed consent
- •3) Confirmed COVID-19 by PCR assay or LAMP assay
- •4) Respiratory failure requiring mechanical ventilation
- •5) Availability of a nasogastric tube
排除标准
- •1) History of Idiopathic pulmonary fibrosis
- •2) History of chronic liver failure (Child Pugh B or C)
- •3) Breastfeeding and pregnancy
- •4) History or proven risk factors of thrombosis
- •5) Proven risk factors of bleeding
- •6) Unavailable to use enteral tube
- •7) Ineligibility for other reasons
研究者
相似试验
招募中
不适用
The safety and efficacy of nintedanib for patients with progressive fibrosing interstitial lung disease in a real world setting-a prospective observational studyProgressive fibrosing interstitial lung diseaseJPRN-UMIN000041380Department of Respiratory Medicine, Juntendo University Hospital300
招募中
不适用
Effects of nintedanib in idiopathic pulmonary fibrosis - analysis on long term prognosis and predictive factorsIdiopathic pulmonary fibrosisJPRN-UMIN000021036ational Hospital Organization Tokyo Medical Center, Department of Respiratory Medicine100
尚未招募
3 期
intedanib the game changer in COVID 19 patientsCTRI/2021/07/035256Self
已完成
不适用
Comparison of the Efficacy of Pirfenidone and Nintedanipine in Pulmonary FibrosisIdiopathic Pulmonary Fibrosis (IPF)NCT06650774Karadeniz Technical University152
已完成
3 期
Nintedanib (BIBF 1120) vs Placebo in Refractory Metastatic Colorectal Cancer (LUME-Colon 1)Colorectal NeoplasmsNCT02149108Boehringer Ingelheim768